Six Biotechs to Know in Barcelona

Why It Matters

The cluster demonstrates Barcelona’s capacity to attract capital and accelerate breakthrough therapies, positioning the region as a competitive alternative to traditional biotech centers in Europe and North America.

Key Takeaways

• Accure's ACT-01 reaches Phase 2 safety success
• Oryzon's iadademstat advances in AML trials
• SpliceBio raises $135M Series B for gene therapy
• Peptomyc's OMO-103 first pan-Myc inhibitor in Phase 2
• Ona Therapeutics secures over $47M for ADC pipeline

Pulse Analysis

Barcelona’s biotech renaissance is anchored by a dense network of research institutes, university hospitals, and the Barcelona Science Park, the country’s first dedicated science hub. The city accounts for 7.6 % of Catalonia’s GDP and has attracted a €1.7 billion health‑campus investment, aiming to generate up to 50,000 jobs. This ecosystem, coupled with strong public‑private funding, creates a fertile ground for innovative drug development and draws multinational interest to Southern Europe.

The six highlighted companies illustrate the breadth of therapeutic approaches emerging from the region. Accure Therapeutics is moving its neuroprotective small‑molecule ACT‑01 through Phase 2, while Oryzon Genomics pushes LSD1 inhibitors like iadademstat into AML and lung‑cancer trials. SpliceBio’s protein‑splicing platform secured a $135 million Series B to advance SB‑007 for Stargardt disease, and Peptomyc’s mini‑protein OMO‑103 became the first pan‑Myc inhibitor to enter Phase 2 for osteosarcoma. Ona Therapeutics bolsters its ADC pipeline with over $47 million in funding, and Integra Therapeutics leverages CRISPR‑Cas and PiggyBac technology, backed by €10.7 million and a €40 million licensing deal, to expand gene‑writing therapies.

For investors and stakeholders, Barcelona’s rising biotech profile signals a shift in the global innovation landscape. The convergence of cutting‑edge science, sizable venture capital, and supportive governmental grants reduces the time to clinic for high‑risk modalities. As these companies progress through pivotal trials, the region is poised to deliver novel treatments for neuro‑degeneration, cancer, and rare genetic disorders, reinforcing Europe’s competitive edge in next‑generation therapeutics.